Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

mission but they have not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the shelf registration statement becomes effective and a final receipt has been issued for the MJDS prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus and a related prospectus supplement.

A written preliminary prospectus included in the registration statement or MJDS prospectus, when available, and meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained at the SEC's website http://www.sec.gov/ , through OncoGenex' website at http://www.oncogenex.com , or via written request to OncoGenex Pharmaceuticals, Inc. at OncoGenex Pharmaceuticals, Inc. at 1522 217th Place SE, Suite 100, Bothell, Washington 98021 U.S.A., Attn: Steve Anderson, Chief Financial Officer, or by telephoning (425) 686-1500. In addition, OncoGenex intends to file a prospectus supplement with the SEC in connection with future offerings, if any, under the shelf registration statement.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Cmed Technology , an eClinical ... and give a presentation about electronic data capture (EDC) ... Ops Executives ( SCOPE ) conference at Florida,s Westin ... As part of SCOPE,s two-day "Electronic Data In ...
... Ky., Feb. 4, 2011 MediVet-America, the leading ... animals suffering from osteoarthritis, hip dysplasia, ligament and ... year of business having achieved record advances in ... Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary ...
... (Pink Sheets: AVXT ) ("AVAX" or the ... with the Securities and Exchange Commission ("SEC").  Upon the ... become a publicly reporting company.  The Company intends to ... Over-the-Counter Bulletin Board.  The Company,s Form 10, which contains ...
Cached Biology Technology:Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year 2AVAX Technologies, Inc. Files Form 10 With SEC 2
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
(Date:7/9/2014)... research has uncovered how a complex protein pivotal in ... is activated. The discovery answers a key question about ... which has been the subject of tens of thousands ... funding. , Jiazhen Zhang, a research student in Professor ... uncovered how the protein complex, called NF-κB, is activated. ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
Breaking Biology News(10 mins):Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3Research reveals how key controller protein is switched on 2UC Riverside plant pathologist receives national recognition 2
... in a jetliner act and feel one way when crammed ... a different mindset when the middle seat is empty and ... parallel that exists among the proteins involved in health and ... issue of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
... Georges Belfort has been recognized for his fundamental ... engineering. Belfort, the Russell Sage Professor of ... weeks received the 2011 Alan S. Michaels Award ... American Chemical Society (ACS) Biotechnology Division. ...
... A fascinating study published in the BMJ shows ... each week, as they drink daily, rather than more on ... disease than the Northern Irish. Ruidavets and colleagues compared groups ... have very different drinking cultures and rates of heart disease.The ...
Cached Biology News:Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2Pattern of drinking affects the relation of alcohol intake to coronary heart disease 2
...
Alexa Fluor 647 anti-mouse Qa-2...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Biology Products: